Major Pharmaceu Patent-Cliff Exposure & CMS Drug Spending Portfolio

Major Pharmaceu (US): 86 reconciled FDA prescription therapies, $73.3M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies86
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$73.3M
2024 Medicare Part D Spend$3K
2024 Medicaid Spend$73.3M
California HCAI SB 17 Filings9 WAC filings (max 459.1% 2-yr change)